05/12/2026
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic O***y Syndrome (PCOS) — a change that accurately reflects the condition, which affects 1 in 8 women, or more than 170 million worldwide. People with MRKH can also have PMOS.
The change follows 14 years of research and advocacy and the largest global engagement ever for a medical name change, with more than 22,000 survey responses, workshops with women who have lived experience, health professionals, and the involvement of 56 patient organisations and professional societies around the world, including ourselves.
The term PCOS focused on “cysts” and ovaries, even though women don’t have cysts. PMOS is a long term endocrine/ hormonal and metabolic condition, and the misunderstanding has contributed to delayed diagnosis, poor quality of care and lack of research and funding.
Women living with the condition led the call for change — and their voices matter ❤️ 86% of patients and 76% of health professionals support the name change.
The change to PMOS will improve understanding, awareness, earlier diagnosis, better care, and more research.
📸
